Theranos' Holmes says investors were future-focused as testimony wraps

Reuters

Published Dec 08, 2021 02:37PM ET

Updated Dec 08, 2021 02:51PM ET

By Jody Godoy

SAN JOSE, Calif. (Reuters) - Theranos founder Elizabeth Holmes finished testifying in her own defense against fraud charges on Wednesday morning, telling jurors that investors "weren't interested in today" but focused on the blood-testing startup's impact in the long-run.

Holmes, 37, faces nine counts of fraud and two counts of conspiracy for allegedly lying about Theranos' technology to bring in cash from wealthy private investors and patients who paid for tests from the company.

Holmes rose to fame in Silicon Valley for her ambitious play to reinvent blood testing with a device that supposedly could perform a diagnostic analysis from a finger prick.

Once valued at $9 billion, Theranos collapsed after the Wall Street Journal published a series of articles, starting in 2015, that suggested its devices were flawed and inaccurate.

Prosecutors allege Holmes' fraud included false claims that Theranos' devices were able to run a range of tests more quickly and accurately than conventional laboratory means.

During her final moments on the stand, Holmes said that she had sought to communicate the future promise of the company to long-term investors.

"I wanted to convey the impact the company could make for people and for healthcare," Holmes said. "They weren't interested in today, tomorrow or next month."